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Abstract
Background: Peripheral skeletal muscle wasting is a common finding with adverse effects in chronic heart failure
(HF). Whereas its clinical relevance is beyond doubt, the underlying pathophysiological mechanisms are not yet
fully elucidated. We aimed to introduce and characterize the primary culture of skeletal muscle cells from individual
HF patients as a supportive model to study this muscle loss.
Methods and results: Primary myoblast and myotubes cultures were successfully propagated from the m. vastus
lateralis of 6 HF patients with reduced ejection fraction (HFrEF; LVEF <45 %) and 6 age and gender-matched healthy
donors. HFrEF cultures were not different from healthy donors in terms of morphology, such as myoblast size, shape
and actin microfilament. Differentiation and fusion indexes were identical between groups. Myoblast proliferation in
logarithmic growth phase, however, was attenuated in the HFrEF group (p = 0.032). In addition, HFrEF myoblasts are
characterized by a reduced TNFR2 expression and IL-6 secretion (p = 0.017 and p = 0.016; respectively).
Conclusion: Biopsy derived primary skeletal muscle myoblasts of HFrEF patients produce similar morphological and
myogenic differentiation responses as myoblasts of healthy donors, though demonstrate loss of anti-inflammatory and
proliferative activity.
Keywords: Chronic heart failure, Muscle wasting, Myoblast cultures, xCELLigence
Background
Skeletal muscle wasting is observed in a variety of chronic
diseases including chronic heart failure (HF) [1–4].
Muscle wasting is present in approximately 70 % of
chronic HF patients [5–7]. The loss of muscle mass during
HF has a significant impact on the patients’ quality of life
and is associated with high morbidity [6]. The mecha-
nisms that underlie HF-related skeletal muscle wasting,
however, are currently not clear. A number of hypotheses
have been put forth to explain the loss of muscle mass,
some of which are physiologic, including prolonged
immobilization and malnutrition, or pathologic, such as
insulin resistance, impaired myogenesis and inflammation.
Until now, mechanistic data generated in this domain
have been confined to animal experiments, human muscle
biopsy specimens, C2C12 mouse myoblasts and L6 myo-
tubes cell lines. Although animal models and immortal-
ized cell lines are convenient sources to study the basic
features of muscle cells, they are devoid of typical human
traits. Specimens of skeletal muscle tissue have been used
mainly to study changes in histologic and (ultra)structural
features. In recent years, however, the primary cell culture
model has gained wide acceptance [8–10]. Studies indi-
cated that human primary skeletal muscle cells adequately
retain phenotypic and genotypic traits of the donor,
including morphological, metabolic and biochemical simi-
larities, in a controlled in vitro environment and hence are
a highly relevant means to study skeletal muscle alter-
ations in vitro [11–13]. Therefore, by generating in vitro
cultures of primary skeletal muscle myoblasts and
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myotubes from HF patients, we may increase the near fu-
ture ability of identifying novel mechanisms contributing
to loss of skeletal muscle mass in this patient population.
In the present study, we aimed to characterize primary
cultures of skeletal muscle from HF origin in relation to
healthy donor cells.
Methods
Patient population and controls
The study population consisted of eight patients with
systolic HF as a result of dilated cardiomyopathy or is-
chemic heart disease, recruited from the Heart Failure
Clinic of the Antwerp University Hospital (Edegem,
Belgium). All patients had a left ventricular ejection frac-
tion (LVEF) of <45 % (HF with reduced EF; HFrEF) and
were classified as New York Heart Association (NYHA)
functional class II-III. Patients were on a stable dose of
HFrEF medication for at least 1 month prior to enroll-
ment. Exclusion criteria were recent acute coronary
syndrome (≤3 months), valvular disease requiring sur-
gery and acute myocarditis or pericarditis. Patients with
acute or chronic infections, allergies, cancer, inflamma-
tory diseases, diabetes mellitus treated with thiazolidine-
diones or fibrates, renal failure and musculoskeletal
abnormalities were excluded to avoid possible metabolic
interference. Eight subjects matched for age and gender,
no medication intake and without any significant medical
history were recruited as controls. The study conforms
with the principles outlined in the Declaration of Helsinki
and was approved by the local Ethics Committee of the
Antwerp University Hospital (committee for medical eth-
ics UZA - UAntwerp). All participants provided written
informed consent before enrollment.
Myoblast cell culture
Biopsy samples were collected of the musculus vastus
lateralis using the Bergstrom needle technique [14].
Muscle specimens were trimmed of connective tissue
and fat, minced into ±1 mm3 fragments and enzymati-
cally dissociated by a series of incubations in 0.05 %
trypsin/EDTA/collagenase. The supernatant of succes-
sive dissociations was centrifuged at 230 x g for 5 min.
The resulting cell suspension was purified from fibro-
blasts by a pre-plating step in collagen-coated 25 cm2
culture flasks containing skeletal muscle growth medium
(SKGM; Lonza, Allendale, NJ) [15]. After 45 min of in-
cubation, the non-adhering cells were transferred into a
new collagen-coated flask. Cells were cultured in a hu-
midified 5 % CO2 atmosphere at 37 °C and growth
medium was refreshed every 2 days until cells reached
70 % confluence. Cultures were tested for myogenicity
by immunostaining using the muscle-specific antibody
desmin (1:100, D1033, Sigma-Aldrich, St. Louis, MO,
USA). Only cultures with a myogenic purity >90 % were
used for further analysis. All experiments were analyzed
blinded and performed at a similar passage 4.
Assessment of myotubes differentiation and fusion index
In order to induce myogenic differentiation of myoblasts,
growth medium was replaced by differentiation medium
consisting of serum free Dulbecco’s Modified Eagle
Medium (DMEM)/Ham’s F-12 (1:1; Lonza) supplemented
with 2 % (v/v) horse serum (Gibco, Life Technologies,
Gent, Belgium). At day 6, cells were fixed in 4 % parafor-
maldehyde. Myotubes and nuclei were visualized by im-
munofluorescence using an antibody against desmin and
4′,6-diamidino-2-phenylindole (DAPI), respectively (see
“in vitro immunocytochemistry section” for details). Myo-
tubes were defined as cells containing at least three nuclei
within one continuous cell membrane [16]. The differenti-
ation index (DI) was calculated as the percentage of
desmin-positive cells in relation to the total number of
nuclei. In order to quantitatively assess the extent of
myoblast fusion, a myogenic fusion index (MFI) was de-
termined as the average number of myogenic nuclei
present in multinucleated myotubes. The fusion index was
analyzed in duplicate by counting at least 250 nuclei from
10 randomly selected fields of view. The deformed myo-
tubes index (DMI) was evaluated as indicated by Yip et al.
and quantified analogously to the MFI [17].
Proliferation kinetics
Myoblast proliferation and viability were continu-
ously monitored using the xCELLigence Real-Time
Cellular Analysis (RTCA) system (Westburg, Leusden,
The Netherlands), according to the manufacturer’s guide-
lines. Briefly, myoblasts were grown in special modified
16-well plates (E-plates) with microelectrodes on the
bottom of each well detecting electrical impedance-based
attachment, spreading and proliferation of the myoblast
cultures. Background impedance (SKGM medium alone)
was measured and cells were seeded at a density of 10.000
cells/well in growth medium. After 30 min at room
temperature (RT) to allow cell attachment, plates were
locked in the RTCA device and electrical impedance was
measured and expressed as a dimensionless parameter
termed cell index (CI), a relative change in electrical im-
pedance representing cell status [18]. The CI was continu-
ously monitored in 15 min intervals with a programmed
signal detection schedule for a total time of 172 h. Two
replicates of each culture were run.
In vitro immunocytochemistry and immunohistochemistry
Cultures were grown on collagen-coated glass chamber
slides at a density of 5x103 cells and allowed to adhere
for 24 h. Next, cells were fixed in 4 % paraformaldehyde
in PBS-D for 20 min at 4 °C and permeabilized in 0.1 %
Triton X-100 in PBS-D for 5 min. Cells were incubated
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with primary antibody overnight and with secondary anti-
body for 1 h. The following primary mouse antibodies were
used: monoclonal anti-desmin (1:200; Sigma-Aldrich),
monoclonal anti-α-actinin (1:100; Sigma-Aldrich) and
monoclonal anti-α-tubulin (1:200; Sigma-Aldrich), and
combined with either a donkey anti-mouse IgG secondary
antibody, Alexa Fluor 546 conjugated (1:800; Molecular
probes, Eugene, OR, USA) or a goat anti-mouse IgG
secondary antibody, Alexa Fluor 546 conjugated (1:800;
Vector Laboratories, Burlingame, CA, USA). Actin micro-
filaments were visualized by applying fluorescein isothio-
cyanate (FITC)-conjugated phalloidin (50 μg/mL in
methanol; Sigma-Aldrich) for 20 min in the dark. Im-
munohistochemical detection of the senescence marker
acetyl-p53 in muscle biopsies and cell cultures was
performed using the primary antibody anti-p53
(Acetyl-Lys317; 1:200; Abcam). Nuclei were counterstained
with DAPI. Cells were visualized using an EVOS fluores-
cent microscope (Westburg, Leusden, The Netherlands).
From each sample, fifteen microphotographs were cap-
tured and analyzed manually. The ultrastructural morph-
ology was analyzed using the software program Image J
(Version 1.45 s, National Institutes of Health, USA). All
specimens were evaluated by two blinded investigators
who were unaware of clinical data and group assignment.
Flow cytometric analysis
Cell cultures were evaluated for muscle specific marker
expression using flow cytometry at several time points
during myogenesis. Cells were trypsinized and centrifuged
at 230 x g for 5 min. The cell pellet was resuspended in
permeabilization buffer for 10 min at a concentration of
1x105 cells/ml and incubated with primary antibodies in
the dark for 30 min. The following primary antibodies
were used: phycoerythrin conjugated mouse anti-human
Pax3 (R&D Systems, Minneapolis, MN, USA), phycoeryth-
rin conjugated rabbit anti-human Pax7 (Bioss Inc.,
Woburn, MA, USA), phycoerythrin conjugated rabbit
anti-human MyoD1 (Bioss Inc.), Alexa fluor 488 conju-
gated mouse anti-human myogenin (R&D Systems) and
rabbit phycoerythrin conjugated anti-human myf6 (MRF4)
(Bioss Inc.). Gating was implemented based on negative
control staining by using mouse IgG1 Alexa 488 conju-
gated and mouse IgG2A (R&D Systems) phycoerythrin
conjugated isotype antibodies (Bioss Inc.). Cell viability
was assessed using the dead cell discriminator dye 7-
aminoactinomycin (7-AAD) and Annexin V-FITC (Becton
Dickinson, Biosciences, Erembodegem, Belgium). Cells
were stained with DRAQ5 (BioStatus Limited; Leicester-
shire, UK) to exclude cellular debris and non-nucleated
cells. Cells were analyzed on a FacsCantoTM II flow cyt-
ometer (Becton Dickinson). A minimum of 30.000 events
was recorded for each analysis. Data analysis was done
with FacsDiva 6.1.2 software. Representative graphs of the
muscle specific marker expressions are provided in
Additional file 1: Figure S1.
Senescence-associated β-galactosidase activity
Senescence-associated beta-galactosidase (SA-β-gal) ac-
tivity was assessed with the β-Galactosidase Staining Kit
(Biovision Research Products, Palo Alto, CA, USA). The
protocol was performed according to the manufacturer’s
instructions. In brief, cells were fixed for 10 min at RT
and incubated overnight in freshly prepared acidic β-gal
staining solution containing 5-bromo-4-chloro-3-indolyl
β-D-galactopyranoside (X-Gal) at 37 °C. Senescence was
determined by phase contrast (Olympus Optical Co.,
Tokyo, Japan) under bright field illumination in 10 ran-
domly selected fields as the ratio of SA-β-gal positive
(blue) cells to the total number of cells. Analyses were
performed in triplicate by two independent observers.
Cytokine production
Concentrations of tumor necrosis factor-α (TNF-α),
interleukin (IL)-6, IL-10, interferon-γ (IFN-γ), and IL-1β
were determined in cell culture supernatant by a multi-
plex enzyme-linked immunosorbent assay (ELISA) tech-
nique based on electrochemiluminescence (Meso Scale
Discovery (MSD) technology, Meso Scale Diagnostics,
Rockville, MD, USA) and according to the manufac-
turer’s instructions. Plates were read on a SECTOR®
Imager 6000 instrument. Data was analyzed using the
Discovery Workbench 3.0 software. All standards and
samples were measured in duplicate.
RNA isolation and quantitative real-time polymerase
chain reaction (RT-PCR)
Total RNA was extracted using the Qiazol reagent tech-
nique followed by RNA cleanup (RNeasy Mini Kit, Qia-
gen). 1 μg of isolated total RNA was reverse-transcribed
using the iScript™ cDNA Synthesis Kit (Bio-rad Laborator-
ies, Nazareth, Belgium). RT-PCR gene-specific forward
and reverse primers (Eurofins MWG Operon; Ebersberg,
Germany) were designed: TNFR1-F: ‘ACC AGG CCG
TGA TCT CTA TG’, TNFR1-R:’CAG CTA TGG CCT
CTC ACT CC’, TNFR2-F:’CTC AGG AGC ATG GGG
ATA AA”, TNFR2-R:’AGC CAG CCA GTC TGA CAT
CT’. PCR amplification with EVAGreen supermix was
performed on a CFX96TM Real-Time PCR Detection sys-
tem (Bio-rad). Gene expression was normalized using the
reference genes TATA box binding protein (TBP) and
beta-2-microglobulin (B2M). Relative quantification of
gene expression levels was performed by analyzing the
RT-PCR data using the delta delta Ct (2-ΔΔCt) calculation.
All samples were run in duplicate.
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Biochemical analyses
Fasted peripheral venous serum was collected from all
HFrEF patients and healthy controls. Creatinine, total
cholesterol, triglycerides, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) cholesterol levels,
glucose and high sensitivity C-reactive protein (hsCRP)
were assessed immediately on Dimension Vista 1500
instrumenten (Siemens Healthcare Diagnostics NV/SA,
Beersel (Huizingen) Belgium) using reagents from Ortho
Clinical Diagnostics. Bioelectrical impedance analysis
was used for assessment of body composition (Omron
body fat monitor BF 300).
Statistical analysis
Experimental triplicates or duplicates were averaged for
statistical analysis. Categorical variables were compared
with the Pearson’s Chi-square (X2) test. Mann-Whitney
U test was used to compare differences between both
groups (HFrEF versus Control). Results are presented as
mean ± standard error of the mean (SEM). Differences
are considered statistically significant if the p-value is
less than 0.05 (P < 0.05). Statistical analyses were per-
formed using SPSS software (IBM SPSS Statistics Inc,
Version 20.0, Chicago, IL, USA).
Results
Patient characteristics
The clinical characteristics of the patients and the
healthy donors are provided in Table 1. All HFrEF
patients received standard HF treatment: 75 % of the
patients received a beta-blocker, 62.5 % an angiotensin
converting enzyme (ACE)-inhibitor, 87.5 % were on
diuretics, 50 % were treated with an angiotensin II
receptor antagonist and 75 % were on statin therapy.
Age, gender and body mass index (BMI) were similar be-
tween groups. HFrEF patients had a pro-inflammatory
blood profile (hsCRP, p = 0.007) and a dyslipidemic state
(triglycerides, p = 0.003) compared to the control group.
Morphological analysis of HFrEF myoblasts
Myoblasts were successfully initiated from six control
subjects and six HFrEF patients (Fig. 1a, b). The percent-
age of desmin-positive myoblasts in each culture was
found to exceed 90 % (91.09 ± 1.89 %, HFrEF vs. 92.14 ±
1.76 %, controls; p = 0.608; Table 2, Fig. 1a–d). The
percentage of desmin-positivity remained similar be-
tween groups during the subsequent differentiation step
(Table 2). No significant differences in myoblast size or
shape were observed between both groups. Myoblasts
presented as small elongated cells to flat slightly
rounded cells. There were also few large multipolar
cells. Cultures were stained for phalloïdin in order to
evaluate the actin microfilament arrangement [19].
Stress fibers were also well-organized in myoblasts of
HFrEF patients (Fig. 1e, f ).
Differentiation of HFrEF myoblasts
Myotubes differentiation (Fig. 2) started at 48–72 h after
the switch from growth to differentiation medium. Mul-
tinucleated myotubes became apparent on a background
of mononucleated myoblasts. The DI was slightly de-
creased in HFrEF myoblast cultures compared to con-
trols (46.57 ± 3.29 % versus 55.49 ± 2.67 %), although this
observation did not reach significance (p = 0.065). Both
cultures grew to normal differentiated myotubes marked
by a very low percentage of deformed myotubes (DMI of
3.10 ± 0.47 %, HFrEF; 1.96 ± 0.36 %, control, p = 0.394).
No significant difference in fusion competence was
observed between myotubes from HFrEF patients and
control subjects (Fig. 2g). Similarly, the size of HFrEF
and control myotubes was not statistically different. The
maturation and sarcomere assembly were evaluated by
means of α-actinin staining and were not different be-
tween groups (Fig. 2a). The α-tubulin and actin filament
networks were also identical in myotubes of HFrEF
patients (Fig. 2d, f ) and controls (Fig. 2c, e).
Quantitative analysis of myoblast viability
The mean numbers of early (Annexin-V+/7-AAD-) and
late apoptotic cells (Annexine-V+/7-AAD+) were not
significantly different between skeletal muscle cells
from HFrEF patients and control subjects (p = 0.352
and p = 0.476, respectively; Table 2).
Proliferative capacity of HFrEF myoblasts
The increase in CI from 50 h to 100 h was less pro-
nounced in myoblasts cultures from HFrEF patients. In
Table 1 Clinical characteristics of HFrEF patients and control
subjects
Characteristic Controls n = 8 HFrEF n = 8 p-value
Age (years) 55 ± 1.8 53 ± 4.5 0.939
Gender (% male) 62.5 % 62.5 % 1.000
Weight (Kg) 83.1 ± 6.4 74.6 ± 6.8 0.367
BMI (Kg/m2) 27.0 ± 1.3 23.3 ± 1.7 0.088
LVEF (%) N.A. 31.3 ± 6.0 N.A.
Total cholesterol (mmol/L) 5.02 ± 0.18 4.45 ± 0.51 0.469
HDL (mmol/L) 1.53 ± 0.15 1.25 ± 0.24 0.101
LDL (mmol/L) 3.05 ± 0.29 2.52 ± 0.42 0.363
Triglycerides (mmol/L) 1.00 ± 0.09 1.77 ± 0.17 0.003
Glucose (mmol/L) 4.75 ± 0.16 5.51 ± 0.39 0.151
Serum Creatinine (mmol/L) 76.91 ± 3.54 103.43 ± 17.68 0.279
hsCRP (mg/L) <2.9 22.0 ± 11.3 0.007
N, Number of subjects; HFrEF, Heart failure with reduced ejection fraction; BMI, Body
mass index; LVEF, Left Ventricular Ejection fraction; HDL, High density lipoprotein;
LDL, Low density lipoprotein; hsCRP, high sensitivity C-reactive protein. Significant
p-values are highlighted in bold. Data are expressed as mean± SEM
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particular, the mean CI taken during the logarithmic
growth phase at 90 h was significantly lower in HFrEF
cultures (p = 0.032). Myoblasts of HFrEF patients
reached their maximum CI at 136.53 ± 5.16 h, whereas
myoblasts of control subjects showed a maximum CI at
114.49 ± 12.05 h (p = 0.214; Fig. 3).
Pax3 and Pax7 expression in HFrEF muscle cells
Satellite cell marker Pax3 showed a low expression (1–2 %)
in both groups of myotubes cultures, indicating the rare
presence of satellite cells (Additional file 1: Figure S1).
Pax7 expression at day 0 was present in 72.72 ± 11.80 % of
myoblasts from HFrEF patients and in 78.82 ± 8.13 % of
myoblasts from controls. The expression level decreased to
51.65 ± 1.86 % and 59.74 ± 2.67 % at day 6 for respectively
HFrEF patients and controls (Additional file 1: Figure S1).
There was no statistically significant difference in Pax7
expression between groups at either time point.
Myogenic regulatory factors in HFrEF muscle cells
The expression of the transcription factors MyoD and
MRF4 remained stable over time during the process of
Fig. 1 Comparative morphological analysis of HFrEF and control myoblasts. Phase contrast (4X) and immunohistochemical (10X) images of
a representative control (a, c) and HFrEF (b, d) culture. Desmin-positive myoblasts (red) are surrounded by few fibroblasts (blue, arrows (⬆)). Actin
microfilament organization using phalloïdin (green) and DAPI (blue) immunostaining of a representative control (e) and HFrEF (f) culture,
20X magnification. Scale bar = 200 μm. N = 6 HF and 6 control cultures
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myogenesis in both myotubes cultures (Additional file 1:
Figure S1). A steady increase in myogenin expression
within 48 h after the change from proliferation to dif-
ferentiation medium was detected in both groups,
with levels reaching 3-fold of those found on day 0
(Additional file 1: Figure S1). Overall, no significant
differences were observed between groups in the percent-
ages of MyoD, Myogenin and MRF4.
Cellular senescence
Muscle biopsies and myoblast cultures from patients and
controls displayed no significant differences regarding cel-
lular senescence. First, the expression of acetyl-p53 was
similar between groups in both muscle biopsies (1.68 ±
0.95 for HFrEF vs. 0.68 ± 0.25 for controls; p = 0.307;
Fig. 4a) and myoblast cultures (1.31 ± 0.42 for HFrEF vs.
1.63 ± 0.41 for controls; p = 0.590; Fig. 4b). Second, myo-
blast cultures of HFrEF patients demonstrated an equal
amount of SA-β-gal positive cells as controls (p = 1.000),
which is in accordance with the results for acetyl-p53
(Fig. 4c). Myoblast cultures of HFrEF patients consisted of
8.06 ± 1.01 % SA-β-gal positive cells, whereas cultures of
controls demonstrated 7.86 ± 0.39 % SA-β-gal positivity.
mRNA expression levels of TNFR1 and TNFR2
No statistical difference was detected for the gene ex-
pression level of the death receptor TNFR1 between
myoblast cultures of patients and controls. In contrast,
TNFR2, which functions as a survival receptor, was sig-
nificantly down-regulated in patient-derived myoblasts
(p = 0.017; Fig. 4d).
Cytokine response in cultured myoblasts
Myoblast cultures at 72 h revealed a significantly
lower IL-6 secretion (p = 0.016) by HFrEF myoblasts
(59.95 ± 18.82 pg/ml) compared to control myoblasts
(226.11 ± 86.07 pg/ml; Fig. 4e). TNF-α secretion was
somewhat increased in HFrEF myoblast cultures, however,
this was not statistically significant (Fig. 4f). In addition,
no significant difference in IL-10 secretion was observed.
Myoblasts did not secrete IL-1β and IFN-γ (mean lower
limits of detection of the assays: 0.04 pg/ml and 0.20 pg/
ml for IL-1 β and IFN-γ, respectively).
Discussion
Human skeletal muscle cell cultures have been exten-
sively studied in chronic diseases such as type 2 diabetes,
obesity and chronic obstructive pulmonary disease
(COPD) [12, 13, 20]. The present study established for
the first time primary cell cultures from the skeletal
muscle of patients with HFrEF and analyzed these for
phenotypic and proliferative characteristics. The main
findings can be summarized as follows:
First, primary myoblasts and myotubes from HFrEF pa-
tients demonstrate a morphology, myogenic differenti-
ation capacity, viability and senescence that is comparable
to muscle cells of healthy donors. Second, myoblasts of
HFrEF patients exhibit an altered proliferative and inflam-
matory activity, supported by the diminished expression
of the survival receptor TNFR2 and lower IL-6 secretion.
In the present study we demonstrate that satellite cell-
derived myoblasts from HFrEF patients are able to differ-
entiate in vitro into multinucleated myotubes. In addition,
we show that skeletal myoblasts and myotubes from pa-
tients with HFrEF have a similar size, shape and myogenic
differentiation ability as muscle cell cultures from healthy
donors. These findings are in line with previous studies in
patients with COPD and type-2 diabetes [20, 21]. In these
patients, the myotubes’ myogenic fusion index and com-
mitment to terminal differentiation were not different
from myotubes of healthy donors. Also, the expression
patterns of the myogenic regulatory factors MyoD, Myo-
genin and MRF4 were similar to healthy donor cultures.
HFrEF myoblasts further demonstrated a delay in pro-
liferation kinetic in comparison to myoblasts of age- and
gender-matched healthy donors. Therefore, it could be
possible that the satellite cells of the HFrEF patients had
already undergone multiple cell divisions in vivo to replen-
ish damaged muscle fibers, resulting in slower culture rates
of cell division. A state of cellular senescence, however, was
not yet detected in the HFrEF myoblasts. Instead, we
Table 2 Myoblast and myotubes characteristics in HFrEF
patients versus controls
Characteristic Controls n = 6 HFrEF n = 6 p-value
Myogenicity (% Desmin positive
cells)
Myoblasts 92.14 ± 1.76 91.09 ± 1.89 0.608
Myotubes 90.80 ± 0.43 92.30 ± 1.19 0.485
Growth characteristics
Maximum cell index (time
in hours)
114.5 ± 12.05 136.5 ± 5.16 0.214
Cell Index (at 90 h) 1.80 ± 0.35 1.0 ± 0.10 0.032
Differentiation capacity
Differentiation Index (DI) 55.49 ± 2.67 46.57 ± 3.29 0.065
Deformed Myotubes Index
(DMI)
1.96 ± 0.36 3.10 ± 0.74 0.394
Myogenic Fusion Index (MFI) 57.33 ± 2.40 50.41 ± 1.98 0.093
< 3 Nuclei 20.67 ± 2.45 26.17 ± 2.55 0.266
3–10 Nuclei 56.50 ± 4.59 50.17 ± 5.89 0.574
> 10 Nuclei 21.17 ± 4.64 18.83 ± 2.63 0.905
Viability (% alive cells)
7-AAD- 97.83 ± 0.51 97.05 ± 0.60 0.476
Annexin-V- 92.25 ± 1.34 90.59 ± 1.66 0.352
N Number of subjects, HFrEF Heart failure with reduced ejection fraction. Significant
p-values are highlighted in bold. Data are expressed as mean± SEM
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observed a reduced expression of the TNF-α receptor
TNFR2, but not of TNFR1. Of note, Torre-Amione et al.
already reported a diminished expression of myocardial
TNFR1 and TNFR2 in patients with advanced HF in 1996
[22]. Recently, patients with HF were found to have ele-
vated levels of circulating soluble TNFR2, which the au-
thors attributed to increased tissue shedding [23].
Furthermore, we observed that the secretion of IL-6 was
significantly reduced in comparison to the IL-6 release by
the healthy donor myoblasts. TNFR1 and TNFR2 are the
two major transducers of TNF-α signals. Ligation of TNF-
α with TNFR1 leads to caspase activation and induces
apoptotic cell death [24]. In contrast, TNFR2 signaling acti-
vates nuclear factor-kappa β (NF-kβ) and signal transducer
and activator of transcription 3 (STAT3), and thereby pro-
motes cell proliferation, cytokine production and cell sur-
vival [25]. IL-6 is a pleiotropic cytokine that is, among
other cells, also produced by growing myofibers and asso-
ciated satellite cells. It stimulates the robust activation and
proliferation of satellite and myoblasts cells in both auto-
crine and paracrine manners via STAT3 signaling, and
therefore acts as a novel mediator in controlling muscle re-
generation [26–28]. In this regard, Serrano et al showed
that if IL-6 is genetically deleted, satellite cell proliferation
Fig. 2 HFrEF and control cultures upon induction of myotubes differentiation. Immunofluorescent images of myogenic cultures from control subjects
(left) and HFrEF patients (right) reacted with antibodies against α-actinin (a, b), α-tubuline (c, d) and phalloïdin (e, f). Magnification of 20X. Nuclei were
stained with DAPI (blue). Quantification of the number of nuclei (N) present in control and HFrEF myoblast cells (g). Scale bar = 200 μm. Data represent
mean ± SEM. (N = 6 controls and HFrEF patients)
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and migration become attenuated, leading to a reduction
in myofiber size [29]. Therefore, based on our findings and
the results from previous studies, it seems that persistent
exposure of skeletal muscle cells to high systemic and local
levels of TNF-α in HFrEF induces a refractory cell state,
provoking a decrease in muscle cell secretion of IL-6 and a
reduction in TNFR2 expression, thereby attenuating cell
proliferation, and this plausibly without affecting the en-
dogenous synthesis of IL-6 [30, 31]. In this regard, in vitro
studies by Hamilton et al. demonstrated that a single 10-h
incubation step of colon cancer cells with TNF-α leads to
endogenous IL-6 through NF-kβ activation and promotes
TNFR2 expression via the autocrine effects of IL-6 [32].
Yet, repeated exposure of cells to TNF-α was shown to
weaken the secretion of IL-6 [33]. Hence, the lower secre-
tion of IL-6 may well contribute to the decrease in prolifer-
ative competitiveness of the HFrEF myoblasts.
Another potential mechanism underlying reduced myo-
blast proliferation in HFrEF is the lack of physical activity
in these patients [34–37]. It has been demonstrated that
both physical training and a single bout of exercise
Fig. 3 Representative growth kinetics of HFrEF and control myoblasts.
Growth curves were generated using the xCELLigence system.
(N = 8 controls and HFrEF patients) *p < 0.05
Fig. 4 Assessment of senescence and inflammatory characteristics. Representative graphs of mean percentage of acetyl-p53 positive cells in muscle
biopsies (a) and myoblast cultures (b). Quantification of the number of SA-β-gal positive cells present in myoblast cells from control subjects and HFrEF
patients (c). mRNA expression level of TNFR2 in myoblasts from HFrEF patients and control subjects (d). IL-6 (e) and TNF-α (f) secretion from cultured
myoblast cells. Data are mean ± SEM. (N = 8 controls and HFrEF patients). *p < 0.05
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positively influence satellite cell function, myoblast prolif-
eration, and cytokine expression and secretion [38–40].
Resistance training, for instance, increases satellite cell
content and activation status, and stimulates satellite cell
proliferation by IL-6 induced activation of STAT3
signaling [41, 42]. Recently, Begue et al. also indicated that
resistance exercise training promotes satellite cell prolifer-
ation by IL-6 induced activation of STAT3 signaling [43].
Furthermore, metabolic disturbances such as hypergly-
caemia, insulin resistance, mitochondrial dysfunction and
a decreased activation of 5′ adenosine monophosphate-
activated protein kinase (AMPK) and p38 mitogen-
activated protein kinase (MAPK) were shown to impair
the proliferation of porcine myoblasts and C2C12 mouse
myoblasts [44–49]. In addition, growth differentiation
factor myostatin was shown to negatively regulate the self-
renewal of satellite cells and to inhibit C2C12 muscle cell
activation, proliferation, myogenic differentiation and pro-
tein synthesis [50–52]. As such, distinct mechanisms
might be involved in the altered inflammatory and prolif-
erative actions of HFrEF myoblasts.
Study limitations
Cells from both HFrEF patients and control subjects
were cultured under the same in vitro environmental
conditions which did not reflect the prevailing inflam-
matory milieu to which skeletal muscles of HFrEF
patients are exposed to in vivo. Circulating TNF-α was
not measured, however, previous studies have indicated
increased serum TNF-α levels in HFrEF [1, 22, 23].
HFrEF patients were on optimal medical treatment and
thus, were administered a number of pharmacological
agents including ACE-inhibitors, beta-blockers, diuretics
and statins. In this regard, and although well-tolerated
by the majority of patients, evidence has indicated that
statins may affect (either positively or negatively) skeletal
muscle function [53–56]. In our study, we observed no
differences in myoblast number, morphology, or differ-
entiation capacity among HFrEF patients on statin ther-
apy (75 % of patients) and those not taking the drug
(25 %). In addition, it has been shown that chronic
kidney disease (CKD), diabetes mellitus and COPD,
common co-morbidities in patients with HFrEF, may
affect muscle cell parameters including proliferation and
differentiation capacities [20, 57, 58]. Therefore, HFrEF
patients with major comorbidities were excluded from
the study. Finally, results are to be confirmed in a wider
range of patients with HFrEF.
Conclusion
In this study, we show that myoblasts derived from
HFrEF patients have altered proliferative and reduced
anti-inflammatory activity if compared to healthy
donor cells. We believe that the in vitro cultivation of
biopsy-derived primary skeletal muscle myoblasts and
myotubes is a promising tool for future research on
muscle wasting in HFrEF.
Additional file
Additional file 1: Figure S1. Differentiation of HFrEF myotubes.
Representative graphs showing the expression pattern of Pax3 (A),
Pax7 (B) and the myogenic regulatory factors MyoD (C), Myogenin
(D) and MRF4 (E) in muscle cells cultivated from HFrEF patients and
control subjects following 6 days in differentiation medium. Satellite cell
marker Pax3 (A) showed a low expression in both groups of myoblasts
cultures indicating the relatively absence of satellite cells. A slightly
increased Pax7 expression was observed within 48 h after having
changed the proliferation medium to differentiation medium (B). As the
myoblasts cultures matured, the level of this transcription factor gradually
decreased whereby the reduction in Pax7 expression was more
pronounced in HFrEF, although not statistically significant myoblasts.
Expression of transcription factors MyoD and MRF4 remained stable
over time during myogenesis (C, E). A steady increase in myogenin
expression within 48 h after the change from proliferation to differentiation
medium was detected in both groups with levels reaching 3-fold of those
found on day 0 (D). Data are mean ± SEM. (N = 6). (PDF 104 kb)
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